Chardan Capital Estimates Immatics FY2026 Earnings

Immatics N.V. (NASDAQ:IMTX) – Research analysts at Chardan Capital issued their FY2026 earnings per share estimates for Immatics in a report released on Monday, October 13th. Chardan Capital analyst Y. Livshits anticipates that the company will earn ($1.53) per share for the year. The consensus estimate for Immatics’ current full-year earnings is ($0.72) per share.

IMTX has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a research report on Wednesday, October 8th. Zacks Research raised Immatics from a “strong sell” rating to a “hold” rating in a report on Monday. Finally, Guggenheim initiated coverage on Immatics in a research report on Thursday, September 18th. They set a “buy” rating and a $16.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Immatics presently has an average rating of “Moderate Buy” and an average target price of $13.67.

Immatics Price Performance

Shares of IMTX opened at $10.83 on Wednesday. The stock has a market capitalization of $1.32 billion, a PE ratio of -16.66 and a beta of 1.22. The business’s fifty day moving average price is $6.96 and its 200 day moving average price is $5.85. Immatics has a 12-month low of $3.30 and a 12-month high of $10.95.

Immatics (NASDAQ:IMTX) last issued its earnings results on Wednesday, August 13th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.28). The firm had revenue of $6.48 million during the quarter, compared to analyst estimates of $13.05 million. Immatics had a negative return on equity of 15.60% and a negative net margin of 59.29%.

Institutional Trading of Immatics

Hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its position in Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after acquiring an additional 2,231 shares during the period. Vontobel Holding Ltd. bought a new stake in shares of Immatics during the second quarter valued at about $59,000. Engineers Gate Manager LP acquired a new stake in Immatics in the second quarter worth about $124,000. Fox Run Management L.L.C. acquired a new stake in Immatics in the second quarter worth about $136,000. Finally, Exchange Traded Concepts LLC grew its position in Immatics by 94.5% in the 1st quarter. Exchange Traded Concepts LLC now owns 25,580 shares of the company’s stock valued at $115,000 after buying an additional 12,425 shares in the last quarter. Institutional investors own 64.41% of the company’s stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.